Pharmicell (KO:005690) — Market Cap & Net Worth
Market Cap & Net Worth: Pharmicell (005690)
Pharmicell (KO:005690) has a market capitalization of $736.42 Million (₩1.09 Trillion) as of May 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #10574 globally and #316 in its home market, demonstrating a 1.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmicell's stock price ₩18110.00 by its total outstanding shares 60004014 (60.00 Million). Analyse Pharmicell cash conversion from operations to see how efficiently the company converts income to cash.
Pharmicell Market Cap History: 2015 to 2026
Pharmicell's market capitalization history from 2015 to 2026. Data shows growth from $171.40 Million to $736.42 Million (12.80% CAGR).
Pharmicell Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmicell's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Pharmicell's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
Pharmicell's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $211.05 Million | $27.84 Billion | -$676.71 Million | 0.01x | N/A |
| 2017 | $231.78 Million | $25.20 Billion | -$39.20 Billion | 0.01x | N/A |
| 2018 | $496.10 Million | $28.35 Billion | -$12.68 Billion | 0.02x | N/A |
| 2019 | $345.24 Million | $32.48 Billion | $4.35 Billion | 0.01x | 0.08x |
| 2020 | $703.48 Million | $37.75 Billion | $5.24 Billion | 0.02x | 0.13x |
| 2021 | $530.66 Million | $51.81 Billion | $9.45 Billion | 0.01x | 0.06x |
| 2022 | $459.50 Million | $60.18 Billion | $8.26 Billion | 0.01x | 0.06x |
| 2023 | $246.83 Million | $56.23 Billion | $3.58 Billion | 0.00x | 0.07x |
| 2024 | $336.70 Million | $64.85 Billion | $6.33 Billion | 0.01x | 0.05x |
Competitor Companies of 005690 by Market Capitalization
Companies near Pharmicell in the global market cap rankings as of May 4, 2026.
Key companies related to Pharmicell by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Pharmicell Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharmicell's market cap moved from $171.40 Million to $ 736.42 Million, with a yearly change of 12.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩736.42 Million | +24.64% |
| 2025 | ₩590.85 Million | +75.48% |
| 2024 | ₩336.70 Million | +36.41% |
| 2023 | ₩246.83 Million | -46.28% |
| 2022 | ₩459.50 Million | -13.41% |
| 2021 | ₩530.66 Million | -24.57% |
| 2020 | ₩703.48 Million | +103.77% |
| 2019 | ₩345.24 Million | -30.41% |
| 2018 | ₩496.10 Million | +114.04% |
| 2017 | ₩231.78 Million | +9.83% |
| 2016 | ₩211.05 Million | +23.13% |
| 2015 | ₩171.40 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Pharmicell was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $736.42 Million USD |
| MoneyControl | $736.42 Million USD |
| MarketWatch | $736.42 Million USD |
| marketcap.company | $736.42 Million USD |
| Reuters | $736.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more